TY - CONF T1 - Autologous stem cell transplantation versus alemtuzumab or ocrelizumab in relapsing remitting multiple sclerosis (starms) JO - MULTIPLE SCLEROSIS JOURNAL PY - 2020/01/01 AU - Sharrack B AU - Snowden J AU - Muraro P ED - VL - 26 IS - 3_SUPPL SP - 209 EP - 210 Y2 - 2025/05/30 ER -